C

CureVac NV

D
CVAC
USD
0.015
(0.4566%)
Market Closed
10,591.00
Volume
-0.15312
EPS
-
Div Yield
-2.365044
P/E
740,236,242.90
Market Cap
Today
0.4566%
1 Week
6.796%
1 Month
0.000%
6 Months
12.628%
12 Months
-57.309%
Year To Date
-21.615%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
MRNA
MRNA
-1.79
(-2.5637%)
USD
B
BNTX
-3
(-2.5972%)
USD
N
NVAX
-0.01
(-0.0796%)
USD
I
INO
-0.09
(-1.3294%)
USD
S
SRNE
(%)
USD

Title:
CureVac NV

Sector:
Healthcare
Industry:
Biotechnology
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
Do you need help or have a question?
Contact Us